Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
Adaptive behavior Measured by: Vineland Adaptive Behavior Scales (parent‐reported scale; mean = 100 (SD = 15); higher score equates to better outcomes) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Autism symptom severity Measured by: parent‐reported autism symptoms on standardised autism screening and diagnostic instruments (lower scores indicate less severe autism symptoms) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Adverse effects Measured by: worsening of adaptive behavior or autism symptom severity · patients with young children (less than six years old) with autism spectrum disorders (ASD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Intelligence Measured by: standardized IQ tests (mean = 100 (SD = 15); higher scores indicate higher IQ) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Communication and language skills: expressive language Measured by: standardized measures of expressive language (higher scores indicate better expressive language skills) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Communication and language skills: receptive language Measured by: standardized measures of receptive language (higher scores indicate better receptive language skills) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Problem behavior Measured by: standardized parent‐report measures and checklists (lower scores indicate lower levels or less severe problem behavior) · patients with young children (less than six years old) with autism spectrum disorders (ASD)
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by a decrease in total inflammatory lesion count, measured in participants who were treated for a minimum period of 16 weeks (Changes from baseline in total inflammatory lesion count and number of participants... · participants with moderate and severe acne
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by physician's global evaluation 20 to 24 weeks · participants with moderate and severe acne
1 finding from 1 review
Regression rate at 6 months · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Nausea · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
1 finding from 1 review
Parental sensitivity · caregiver‐infant dyads
1 finding from 1 review